# Fasenra (benralizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/benralizumab

> The FDA approved Fasenra (benralizumab), sponsored by ASTRAZENECA PLC (AZN), on November 14, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Fasenra (benralizumab) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | Severe Eosinophilic Asthma, [Hypereosinophilic Syndrome](https://sec-api.dev/indications/hypereosinophilic-syndrome), [Eosinophilic Asthma](https://sec-api.dev/indications/eosinophilic-asthma), [Asthma](https://sec-api.dev/indications/asthma), Eosinophilic Granulomatosis With Polyangiitis (EGPA), [Chronic Obstructive Pulmonary Disease](https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease) |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### November 14, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761070 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171114, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22

### April 5, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761070 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20240405, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22

### September 17, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761070 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22

### May 7, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." https://clinicaltrials.gov/study/NCT04191304

### July 28, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04053634 (Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT04053634

### May 13, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761070 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260513, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FASENRA (BENRALIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761070%22

### May 13, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Severe Eosinophilic Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06465485 (STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06465485

### July 10, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." https://clinicaltrials.gov/study/NCT04191304?tab=results

### September 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Eosinophilic Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06750289

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Eosinophilic Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06750289 (Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06750289

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05692180

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT05692180

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06512883 (A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-20 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06512883

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06512883 (A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-20 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06512883

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07444567 (Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-27 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07444567

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07444567 (Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-27 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07444567

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340) (SNY)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [Tozorakimab dose regimen 1](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) (AZN)
- [Treatment a : budesonide, glycopyrronium, and formoterol fumarate](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) (AZN)
- [Verekitug](https://sec-api.dev/pdufa/verekitug) (UPB)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [February 2028](https://sec-api.dev/fda-calendar/2028-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/benralizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fasenra (benralizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/benralizumab

```bibtex
@misc{secapidev_pdufa_benralizumab_20261116,
  title        = {Fasenra (benralizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/benralizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_benralizumab_20261116","title":"Fasenra (benralizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/benralizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
